09:11 AM EDT, 10/02/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Wednesday that it has signed non-exclusive, royalty-free voluntary licensing deals with six pharmaceutical companies to manufacture and sell generic lenacapavir for the prevention of HIV in 120 mostly low-income countries.

The pharmaceutical companies include Dr. Reddy's Laboratories (RDY), Emcure, Eva Pharma, Ferozsons Laboratories, Hetero Drugs, and Viatris ( VTRS ) subsidiary Myla.

Gilead said it plans to price the product at no profit to the company.

The company also said the six licensees will build manufacturing capacity for lenacapavir "as quickly as possible."

Price: 83.70, Change: -0.24, Percent Change: -0.29